exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087771 RNA Name: hsa-miR-142-3p RNA Type: miRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 58331245 End Site(bp): 58331267 External Links: hsa-miR-142-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BLOC1S6 chr15 45587214 45615945 + BOD1 chr5 173607145 173616659 - CUL5 chr11 108008898 108107761 + ETFRF1 chr12 25195216 25209645 + SEMA7A chr15 74409289 74433958 - TNRC6B chr22 40044817 40335808 + ZNF676 chr19 22179089 22215801 - AL139011.2 chr1 160216800 160285130 - B2M chr15 44711487 44718877 + CCDC126 chr7 23597382 23644708 + EEF1A1 chr6 73515750 73523797 - MAST2 chr1 45786987 46036122 + MBD3 chr19 1573596 1592865 - MRPL18 chr6 159789812 159798436 + NDUFA2 chr5 140638740 140647785 - PEX19 chr1 160276812 160286348 - PRDX1 chr1 45511036 45523047 - RPL27 chr17 42998273 43002959 + SLC35F5 chr2 113705011 113756693 - SPDL1 chr5 169583636 169604778 + TMSB4X chrX 12975110 12977227 + VPS53 chr17 508668 721717 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000120 chr1 117944807 118009049 + hsa_circ_0001387 chr4 1902352 1936989 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004687.1 chr17 58330884 58332508 - AC011815.1 chr18 35280867 35290201 - AC126365.1 chr17 20788071 20789584 + FGD5-AS1 chr3 14920347 14948424 - MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + AC138761.1 chr17 22266395 22288301 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.